Weekly Digest – December 2024 Weekly Digest – December 2024 19 Dec 2024: Pyxis oncology announces portfolio prioritization, focusing resources on its lead clinical program, PYX-201 Pyxis Oncology announced a portfolio prioritization to focus on advancing its lead clinical program, […]
Weekly Digest – December 2024 Weekly Digest – December 2024 19 Dec 2024: CStone announces first patient enrolled in the global multicenter phase 1b clinical trial of CS5001 (ROR1 ADC) CStone Pharmaceuticals announced the enrollment of the first patient in […]
Weekly Digest – December 2024 Weekly Digest – December 2024 16 Dec 2024: Biocytogen announces Adcendo ApS exercises antibody option to accelerate ADC development Biocytogen Pharmaceuticals announced that Adcendo ApS has exercised its option under a research, option, and license […]
Weekly Digest – December 2024 Weekly Digest – December 2024 18 Dec 2024: MediLink announces YL201 granted orphan-drug designation by the US FDA MediLink Therapeutics announced that the FDA has granted Orphan-Drug Designation to YL201 for the treatment of small […]
Weekly Digest – December 2024 Weekly Digest – December 2024 17 Dec 2024: FDA grants breakthrough therapy designation to sacituzumab govitecan for second-line ES-SCLC The FDA granted breakthrough therapy designation to sacituzumab govitecan-hziy for patients with extensive-stage small cell lung […]
Weekly Digest – December 2024 Weekly Digest – December 2024 16 Dec 2024: GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer The European Medicines Agency (EMA) granted PRIME Designation to GSK’227, […]
